TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Burning Rock Biotech ( (BNR) ) is now available.
Burning Rock Biotech reported its financial results for the third quarter of 2025, highlighting a 2.3% increase in total revenues compared to the same period in 2024. The company experienced a significant increase in revenue from pharma research and development services, while revenues from in-hospital and central laboratory businesses decreased. The company’s gross profit improved by 7.6%, with a notable increase in gross margin due to high-margin companion diagnostic projects. Operating expenses decreased by 11.9%, driven by cost control measures and headcount reduction. Despite a net loss of RMB16.8 million, this was a substantial improvement from the previous year’s loss.
The most recent analyst rating on (BNR) stock is a Hold with a $16.00 price target. To see the full list of analyst forecasts on Burning Rock Biotech stock, see the BNR Stock Forecast page.
Spark’s Take on BNR Stock
According to Spark, TipRanks’ AI Analyst, BNR is a Neutral.
Burning Rock Biotech’s overall stock score is driven by strong technical momentum, despite significant financial challenges and valuation concerns. The stock’s price is supported by bullish technical indicators, but the lack of profitability and negative cash flows weigh heavily on its financial performance. Investors should be cautious of the high beta, indicating potential volatility.
To see Spark’s full report on BNR stock, click here.
More about Burning Rock Biotech
Burning Rock Biotech Limited is a company focused on the application of next generation sequencing (NGS) technology in precision oncology. The company provides NGS-based therapy selection testing for late-stage cancer patients and is advancing cancer early detection from research to clinical validation.
Average Trading Volume: 30,848
Technical Sentiment Signal: Buy
Current Market Cap: $172.6M
Find detailed analytics on BNR stock on TipRanks’ Stock Analysis page.